natgillin/translations-raw huggingface dataset:
(anvendes til at forebygge og behandle mavesår, halsbrand og opstød) dexamethason (et kortikosteroid-lægemiddel, som anvendes til at behandle betændelse og undertrykke immunforsvaret), hvis det indtages gennem munden eller indsprøjtes (undtagen hvis behandlingen kun består af en enkelt dosis) produkter, der indeholder perikon (Hypericum perforatum) (et naturlægemiddel, der anvendes til depression og angst)
omeprazole, dexlansoprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole (used to prevent and treat stomach ulcers, heartburn, acid reflux disease) dexamethasone (a corticosteroid medicine used to treat inflammation and suppress the immune system) when taken by mouth or injected (except as a single dose treatment) products that contain St. John's wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety)
Sikkerheden og virkningen af E/C/F/TAF blev evalueret i det ublindede studie GS-US-292-1249 hos voksne patienter med samtidig infektion med hiv-1 og kronisk hepatitis B. 69 ud af de 72 patienter havde tidligere fået TDF-baseret antiretroviral behandling.
In open-label Study GS-US-292-1249, the efficacy and safety of E/C/F/TAF were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy.
Patienterne havde en gennemsnitsalder på 45 år (23-72), 90 % var mænd, 75 % var hvide, og 19 % var sorte.
Patients had a mean age of 45 years (range 23-72), 90% were male, 75% were White, and 19% were Black.
0 % (95 % CI: -4,8 % til 4,8 %)
0% (95% CI: -4.8% to 4.8%)
Virologisk supprimerede hiv 1-inficerede voksne patienter Studie GS-US-366-1216, et randomiseret, dobbeltblindt studie hos virologisk supprimerede hiv 1inficerede voksne, evaluerede effekten og sikkerheden ved skift fra FTC/RVP/TDF til Odefsey.
Virologically suppressed HIV-1 infected adult patients In Study GS-US-366-1216, the efficacy and safety of switching from FTC/RPV/TDF to Odefsey were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults.
-0,3 % (95 % CI: -4,2 % til 3,7 %)
-0.3% (95% CI: -4.2% to 3.7%)
Patienterne havde en gennemsnitsalder på 48 år (19-76), 87% var mænd, 67 % var hvide, og 27 % var sorte.
Patients had a mean age of 48 years (range 19-76), 87% were male, 67% were White, and 27% were Black.
Kombinationen af Odefsey og disse makrolidantibiotika kan medføre et fald i plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp).
The combination of Odefsey with these macrolide antibiotics may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Det gennemsnitlige CD4+ celletal ved baseline var 664 celler/mm3 (interval: 126-1.813).
The mean baseline CD4+ cell count was 664 cells/mm3 (range 126-1,813).
tenofoviralafenamid tenofovirdisoproxil lamivudin adefovirdipivoxil
tenofovir alafenamide tenofovir disoproxil lamivudine adefovir dipivoxil
Sikkerheden af emtricitabin + tenofoviralafenamid blev evalueret til og med 48 uger i et ublindet klinisk studie (GS-US-292-0106), hvor 50 hiv 1-inficerede, behandlingsnaive pædiatriske patienter i alderen 12 til < 18 år fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat som en fastdosis kombinationstablet.
The safety of emtricitabine + tenofovir alafenamide was evaluated through 48 weeks in an open-label clinical study (GS-US-292-0106) in which 50 HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet.
I et studie hos virologisk supprimerede patienter, der skiftede fra EFV/FTC/TDF til Odefsey (studie GS-US-366-1160), blev der observeret fald fra baseline i værdier ved faste for total-kolesterol og HDL-kolesterol i Odefsey-armen.
In a study of virologically suppressed patients switching from EFV/FTC/TDF to Odefsey (Study GS-US-366-1160), decreases from baseline were observed in the fasting values of total cholesterol and HDL-cholesterol in the Odefsey arm; no clinically relevant changes from baseline in median fasting values for total cholesterol to HDL-cholesterol ratio, direct LDL-cholesterol or triglycerides were observed in either treatment arm at Week 96.
5 Bivirkning identificeret under sikkerhedsovervågning efter markedsføring for lægemidler indeholdende emtricitabin.. 6 Bivirkning identificeret under sikkerhedsovervågning efter markedsføring for lægemidler indeholdende tenofoviralafenamid.
5 Adverse reaction identified through post-marketing surveillance for emtricitabine-containing products.
træthed1,3
fatigue1, 3
Administration af Odefsey sammen med lægemidler, der inducerer CYP3A, er blevet vist at nedsætte plasmakoncentrationerne af rilpivirin, hvilket potentielt kan medføre svigtende virologisk respons på Odefsey (se pkt.
Co-administration of Odefsey and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Antivirale midler Ledipasvir/sofosbuvir (90 mg/400 mg en gang dagligt)/ rilpivirin
Antiviral agents Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Rilpivirine
Rifabutin (300 mg en gang dagligt)/rilpivirin1
Rifabutin (300 mg once daily)/ Rilpivirine1
Indtil uge 96 havde færre patienter i rilpivirin-armen med en virusbelastning ved baseline ≤ 100.000 kopier/ml nyopstået resistens-associerede substitutioner og/eller fænotyperesistens over for rilpivirin (7/288) end patienter med en virusbelastning ved baseline > 100.000 kopier/ml (30/262).
had emerging resistance-associated substitutions and/or phenotypic resistance to rilpivirine (7/288) than patients with baseline viral load > 100,000 copies/mL (30/262).
Samtidig administration medfører sandsynligvis et signifikant fald i plasmakoncentrationerne af tenofoviralafenamid (induktion af P-gp).
Co-administration is likely to cause significant decreases in the plasma concentrations of tenofovir alafenamide (induction of P-gp).
Ledipasvir/sofosbuvir (90 mg/400 mg en gang dagligt)/ tenofoviralafenamid
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Tenofovir alafenamide
Imidlertid metaboliseres emtricitabin ikke signifikant af leverenzymer, så påvirkningen af nedsat leverfunktion bør være begrænset.
The pharmacokinetics of emtricitabine have not been studied in patients with varying degrees of hepatic insufficiency; however emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Famotidin (enkeltdosis på 40 mg taget 12 timer før rilpivirin)/ rilpivirin1
Famotidine (40 mg single dose taken 12 hours before rilpivirine)/ Rilpivirine1
Norethindron (1 mg en gang dagligt)/rilpivirin
Norethindrone (1 mg once daily)/ Rilpivirine
4,1 % (95 % CI: 1,6 % til 6,7 %, p < 0,001c)
2.0% (95% CI: -0.7% to 4.7%) 4.2% (95% CI: 0.6% to 7.8%) 4.1% (95% CI: 1.6% to 6.7%, p < 0.001c)
Andelen af respondere var højere for forsøgspersoner med en virusbelastning ved baseline ≤ 100.000 kopier/ml (78,6 %, 22/28) i forhold til dem med en virusbelastning ved baseline > 100.000 kopier/ml (50,0 %, 4/8).
(78.6%, 22/28) as compared to those with a baseline viral load > 100,000 copies/mL (50.0%, 4/8).
Famotidin (enkeltdosis på 40 mg taget 4 timer efter rilpivirin)/ rilpivirin1
Famotidine (40 mg single dose taken 4 hours after rilpivirine)/ Rilpivirine1
Rifabutin (300 mg en gang dagligt)/rilpivirin
Rifabutin (300 mg once daily)/ Rilpivirine
Famotidin (enkeltdosis på 40 mg taget 2 timer før rilpivirin)/ rilpivirin1
Famotidine (40 mg single dose taken 2 hours before rilpivirine)/ Rilpivirine1
Sådan skal De tage Odefsey
How to take Odefsey
0,7 % (95 % CI: -4,3 % til 5,8 %)
0.7% (95% CI: -4.3% to 5.8%)
Sikkerheden af emtricitabin + tenofoviralafenamid blev evalueret til og med 48 uger i et ublindet klinisk studie med én behandlingsarm (GS-US-292-1825), hvor 55 hiv 1-inficerede patienter, der var virologisk supprimerede med nyresygdom i slutstadiet (eGFRCG < 15 ml/min) i kronisk hæmodialyse fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat som en fastdosis kombinationstablet.
The safety of emtricitabine + tenofovir alafenamide was evaluated through 48 weeks in a single arm, open-label clinical study (GS-US-292-1825) in which 55 virologically suppressed HIV-1 infected patients with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet.
Hvis De tager et syreneutraliserende middel, skal De tage det mindst 2 timer før eller mindst 4 timer efter Odefsey.
If you are taking an antacid, take it at least 2 hours before or at least 4 hours after Odefsey.
Samtidig administration kan medføre signifikante fald i plasmakoncentrationerne af rilpivirin (induktion af CYP3A) og tenofoviralafenamid (induktion af P-gp).
Co-administration may cause significant decreases in the plasma concentrations of rilpivirine (induction of CYP3A) and tenofovir alafenamide (induction of P-gp).
Farmakoterapeutisk klassifikation: Antiviralt middel til systemisk brug.
Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations, ATC code: J05AR19
Gennemsnitlig procentvis ændring i AUC, Cmax, Cmin
Mean percent change in AUC,
 Hvis dette gælder for Dem, må De ikke tage Odefsey.
 If this applies to you, do not take Odefsey and tell your doctor immediately.
S(+) metadon: AUC: ↓ 16 % Cmin: ↓ 21 % Cmax: ↓ 13 %
AUC: ↓ 16% Cmin: ↓ 21% Cmax: ↓ 13%
Samtidig administration vil sandsynligvis medføre signifikante fald i plasmakoncentrationerne af rilpivirin (induktion af CYP3A) og tenofoviralafenamid (induktion af P-gp).
Co-administration is likely to cause significant decreases in the plasma concentrations of rilpivirine (induction of CYP3A) and tenofovir alafenamide (induction of P-gp).
Ved uge 48 havde 81,8 % (45/55 patienter) stadig hiv 1-rna < 50 kopier/ml, efter de var skiftet til E/C/F/TAF, Der var ingen klinisk signifikante ændringer i fastende laboratorieprøver for lipider hos patienter, som skiftede.
At Week 48, 81.8% (45/55 patients) maintained HIV-1 RNA < 50 copies/mL after switching to E/C/F/TAF.
udslæt1,3
rash1, 3
Sofosbuvir/velpatasvir/voxilapre vir (400 mg/100 mg/100 mg + 100 mg en gang dagligt3)/ emtricitabin/rilpivirin/ tenofoviralafenamid (200 mg/25 mg/25 mg en gang dagligt)
Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg + 100 mg once daily)3/
AUC: ↓ 80 % Cmin: ↓ 89 % Cmax: ↓ 69 % Induktion af CYP3A
AUC: ↓ 80% Cmin: ↓ 89% Cmax: ↓ 69%
Studie GS-US-366-1160, et randomiseret, dobbeltblindt studie hos virologisk supprimerede hiv 1-inficerede voksne, evaluerede effekten og sikkerheden ved skift fra EVF/FTC/TDF til Odefsey.
In Study GS-US-366-1160, the efficacy and safety of switching from EFV/FTC/TDF to Odefsey were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults.
• Hvis De kommer i tanker om det 12 timer eller længere efter det tidspunkt, De normalt tager
• If you notice 12 hours or more after the time you usually take Odefsey, then do not take the missed dose.
Samtidig administration af ciclosporin forventes at øge plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp).
Co-administration of ciclosporin is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Samtidig administration af disse antimykotika forventes at øge plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp).
Co-administration of these antifungal agents is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
AUC: ↓ 42 % Cmin: ↓ 48 % Cmax: ↓ 31 % Induktion af CYP3A
AUC: ↓ 42% Cmin: ↓ 48% Cmax: ↓ 31%
Cmin: ↑76 % Cmax: ↑ 30 %
AUC: ↑ 49% Cmin: ↑ 76% Cmax: ↑ 30%
Det skal De vide, før De begynder at tage Odefsey Sådan skal De tage Odefsey Bivirkninger
What Odefsey is and what it is used for What you need to know before you take Odefsey How to take Odefsey
nedsat leukocyttal1, nedsat hæmoglobin1, nedsat trombocyttal1
decreased white blood cell count1, decreased haemoglobin1, decreased platelet count1
R(-) metadon: AUC: ↓ 16 % Cmin: ↓ 22 % Cmax: ↓ 14 %
AUC: ↓ 16% Cmin: ↓ 22% Cmax: ↓ 14%
Ethinylestradiol: AUC: ↔
Ethinylestradiol:
Tenofoviralafenamid: AUC: ↑ 32 % Cmax: ↑ 3 %
AUC: ↑ 32% Cmax: ↑ 3%
AUC: ↔ Cmin: ↑ 26 %
AUC: ↔ Cmin: ↑ 26% Cmax: ↔
Leversygdom
Cardiovascular
• mundtørhed
• tiredness
Cmin: ↑ 10 %
Cmax: ↑ 21%
5,4 % (95 % CI: 1,5 % til 9,2 %)
0.4% (95% CI: -3.0% to 3.8%) 5.4% (95% CI: 1.5% to 9.2%)
Mave-tarm-kanalen Meget almindelig:
Hepatobiliary disorders Very common:
Ketoconazol: AUC: ↓ 24 % Cmin: ↓ 66 %
AUC: ↓ 24% Cmin: ↓ 66% Cmax: ↔
Regimer med rilpivirin
Rilpivirine-containing regimen
Hvis De har taget for mange Odefsey
If you take more Odefsey than you should
1216), blev der observeret stigninger fra baseline i faste-værdier for total-kolesterol, direkteLDL-kolesterol, HDL-kolesterol og triglycerider i Odefsey-armen.
In a study of virologically suppressed patients switching from FTC/RPV/TDF to Odefsey (Study GS-US-366-1216), increases from baseline were observed in fasting values of total cholesterol, direct LDL-cholesterol, HDL-cholesterol, and triglycerides in the Odefsey arm; and no clinically relevant changes from baseline in median fasting values for total cholesterol to HDL-cholesterol ratio were observed in either treatment arm at Week 96.
Osteonekrose
Norelgestromin:
Virkningen holdt sig i næsten et år.
This effect was maintained for almost one year.
Sylvant fik en markedsføringstilladelse med gyldighed i hele EU den 22. maj 2014.
Sylvant received a marketing authorisation valid throughout the EU on 22 May 2014.
Den anbefalede dosis er 11 mg pr. kg legemsvægt, og infusionen bør vare ca. en time.
The recommended dose is 11 mg per kilogram body weight, and the infusion should last around one hour.
Sylvant gives hver tredje uge, indtil patienten ikke længere har gavn af behandlingen.
Sylvant is given every three weeks, until the patient no longer benefits from treatment.
Udvalget anerkendte desuden, at der er et udækket medicinsk behov hos disse patienter.
The Agency also acknowledged that there is an unmet medical need for these patients.
Andre oplysninger om Sylvant
Other information about Sylvant
Som for alle lægemidler bliver data vedrørende brugen af Sylvant løbende overvåget.
As for all medicines, data on the use of Sylvant are continuously monitored.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Sylvant?
What measures are being taken to ensure the safe and effective use of Sylvant?
Bivirkningerne af Sylvant blev anset for acceptable, men der bør indsamles flere langsigtede data.
Side effects of Sylvant were considered acceptable but further long-term data are to be collected.
Virksomheden skal sørge for, at sundhedspersoner, der forventes at anvende lægemidlet, får udleveret oplysninger om, hvordan de indfører deres patienter i registret.
The company will ensure that healthcare professionals who are expected to use the medicine are provided with information on how to enter their patients in the registry.
Et monoklonalt antistof er et protein, der er udformet, så det genkender og bindes til en særlig struktur (et antigen) i kroppen.
A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) in the body.
Den alvorligste bivirkning er en svær allergisk reaktion (anafylaksi).
The most serious side effect is anaphylactic reaction (a severe allergic reaction).
Castlemans sygdom er sjælden, og Sylvant blev udpeget som "lægemiddel til sjældne sygdomme" den 30. november 2007.
Castleman's disease is rare, and Sylvant was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 November 2007.
Hvorfor blev Sylvant godkendt i EU?
Why is Sylvant authorised in the EU?
Virksomheden, der markedsfører Sylvant, skal oprette et patientregister, der kan give flere oplysninger om den langsigtede sikkerhed.
The company that markets Sylvant is required to set up a patient registry to provide further data on long-term safety.
Yderligere information om Sylvant findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Further information on Sylvant can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
En oversigt over Sylvant, og hvorfor det er godkendt i EU
An overview of Sylvant and why it is authorised in the EU
Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Sylvant opvejer risiciene, og at det kan godkendes til anvendelse i EU.
The European Medicines Agency decided that Sylvant's benefits are greater than its risks and it can be authorised for use in the EU.
Hvad er Sylvant, og hvad anvendes det til?
What is Sylvant and what is it used for?
Indberettede bivirkninger ved Sylvant vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
Side effects reported with Sylvant are carefully evaluated and any necessary action taken to protect patients.
I de første 12 måneder af behandlingen skal patienten have taget blodprøver før hver dosis af Sylvant, derefter hver 9. uge; ved abnorme blodprøver eller ved visse bivirkninger kan det nødvendigt at udsætte behandlingen.
During the first 12 months of treatment the patient should have a blood test before each dose of Sylvant, and every nine weeks afterwards; treatment may need to be delayed in patients whose blood tests are abnormal or who have certain side effects.
Agenturet konkluderede, at Sylvant er påvist at have gavnlig virkning i form af mindskelse af svulsternes størrelse og symptomerne hos patienter med multicentrisk Castlemans sygdom, og at denne positive virkning ser ud til at vedvare.
The Agency concluded that Sylvant has shown beneficial effect by reducing tumour size and symptoms in patients with multicentric Castleman's disease, and that this positive effect seems to be maintained over time.
Hvilke risici er der forbundet med Sylvant?
What are the risks associated with Sylvant?
Virkningen aflægemidlet blev sammenlignet med en uvirksom behandling (placebo), og det vigtigste mål for virkningen var den andel af patienterne, der reagerede på behandlingen i mindst 18 uger, som det fremgik af en reduktion på 50 % ("delvis respons") eller fuldstændig forsvinden ('komplet respons') af svulster og sygdomssymptomer.
The effect of the medicine was compared with placebo (a dummy treatment) and the main measure of effectiveness was the proportion of patients who responded to treatment for at least 18 weeks, as shown by a 50% reduction (‘partial response') or complete disappearance (‘complete response') of tumours and symptoms of the disease.
For mere information om brug af Sylvant se indlægssedlen, eller kontakt lægen eller apotekspersonalet.
For more information about using Sylvant, see the summary of product characteristics or contact a doctor or pharmacist.
Med multicentrisk menes, at sygdommen omfatter flere lymfeknuder foruden andre organer i kroppen.
Multicentric means that the disease affects several lymph nodes as well as other organs in the body.
Sylvant udleveres kun efter recept, og behandlingen bør iværksættes og overvåges af uddannet sundhedspersonale under tilstrækkeligt lægeligt opsyn.
Sylvant can only be obtained with a prescription and treatment should be given by qualified healthcare professionals and under appropriate medical supervision.
Det gives gennem et drop (ved infusion) i en vene.
It is given by infusion (drip) into a vein.
Det aktive stof i Sylvant, siltuximab, er et monoklonalt antistof.
The active substance in Sylvant, siltuximab, is a monoclonal antibody.
De hyppigste bivirkninger ved Sylvant (som optræder hos mere end 1 ud af 5 patienter) er infektioner (herunder infektioner i øvre luftveje som næse og svælg), kløe, udslæt, ledsmerter og diarré.
The most common side effects with Sylvant (which may affect more than 1 in 5 people) are infections (including upper respiratory tract infections such as those of the throat and nose), itching, rash, joint pain and diarrhoea.
Sylvant er undersøgt i ét hovedstudie med 79 voksne, som havde multicentrisk Castlemans sygdom, men ikke hiv- eller HHV-8-infektion.
Sylvant has been investigated in one main study involving 79 adults with multicentric Castleman's disease who did not have HIV or HHV-8 infection.
Siltuximab er udformet, så det bindes til kroppens protein interleukin 6 (IL-6).
Siltuximab has been designed to attach to a protein in the body called interleukin 6 (IL-6).
Sylvant anvendes til behandling af multicentrisk Castlemans sygdom hos voksne, der ikke er smittet med humant immundefektvirus (hiv) eller humant herpesvirus-8 (HHV-8).
Sylvant is a medicine that is used to treat multicentric Castleman's disease in adults who are not infected with human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8).
Sylvant indeholder det aktive stof siltuximab.
Sylvant contains the active substance siltuximab.
Symptomerne kan være træthed, natlige svedudbrud, feber, prikken og stikken som følge af nervebeskadigelse (perifer neuropati) og forstørret lever og milt.
Symptoms can include tiredness, sweating at night, fever, peripheral neuropathy (pins and needles due to nerve damage) and swelling of liver and spleen.
Den fuldstændige liste over bivirkninger og begrænsninger ved Sylvant fremgår af indlægssedlen.
For the full list of side effects and restrictions of Sylvant, see the package leaflet.
Sylvant var mere effektivt end placebo til at få svulster og sygdomssymptomer til at svinde: 17 ud af 53 patienter, som fik Sylvant, udviste delvis respons, og én udviste komplet respons.
Sylvant was more effective than placebo in reducing tumour size and disease symptoms: 17 out of 53 patients who received Sylvant showed a partial response and one showed a complete response, compared with none of the 26 patients who received placebo.
Når siltuximab bindes til IL-6, blokerer det dets aktivitet og standser den abnorme cellevækst, så lymfeknuderne bliver mindre, og sygdomssymptomerne aftager.
By attaching to IL-6, siltuximab blocks its activity and stops abnormal cell growth, thus reducing the size of the lymph nodes and the symptoms of the disease.
Hvordan anvendes Sylvant?
How is Sylvant used?
Hvordan virker Sylvant?
How does Sylvant work?
Hvilke fordele viser studierne, at der er ved Sylvant?
What benefits of Sylvant have been shown in studies?
Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Sylvant.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sylvant have also been included in the summary of product characteristics and the package leaflet.
Castlemans sygdom er en sygdom i lymfesystemet, dvs. det netværk af kar, der transporterer væske fra vævene gennem lymfeknuderne til blodbanen.
Castleman's disease is a disorder of the lymphatic system (a network of vessels that transport fluid from tissues through the lymph nodes and into the bloodstream) in which cells in lymph nodes start growing abnormally, causing benign tumours.
Patienter med Castlemans sygdom producerer for meget IL-6.
Patients with Castleman's disease produce too much IL-6 and this is thought to contribute to the abnormal growth of certain cells in the lymph nodes.
Derefter skal barnet have vand eller mælk for at sluge granulatet.
The child should then be given water or milk to swallow the granules.
Den valgte dosis er den lavest mulige til kontrol af barnets symptomer.
The dose is chosen to be lowest possible that controls the child's symptoms.